Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06159660




Registration number
NCT06159660
Ethics application status
Date submitted
22/08/2023
Date registered
7/12/2023

Titles & IDs
Public title
Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy
Scientific title
Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy
Secondary ID [1] 0 0
IX-2023-OV-VENTURE
Universal Trial Number (UTN)
Trial acronym
VENTURE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lung Neoplasm 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Physiological accuracy of X-ray-based ventilation imaging (BHCT, fluoroscopy, 4DCBCT, 4DCT)
Timepoint [1] 0 0
1 week
Secondary outcome [1] 0 0
Difference in mean dose to high functioning lung structures between avoidance treatment plans and standard of care anatomical based treatment plans.
Timepoint [1] 0 0
1 week
Secondary outcome [2] 0 0
Difference in percentage volume of high functioning lung structures receiving 20 Gray (20Gy) or more between functional lung avoidance treatment plans and standard of care anatomical based treatment plans.
Timepoint [2] 0 0
1 week
Secondary outcome [3] 0 0
Reduction in predicted risk of grade 2+ radiation pneumonitis (CTCAE v5) in functional lung avoidance treatment plans compared to standard of care anatomical based treatment plans.
Timepoint [3] 0 0
1 week
Secondary outcome [4] 0 0
Increased burden in the radiotherapy workflow involved with creating functional lung avoidance treatment plans.
Timepoint [4] 0 0
2 weeks
Secondary outcome [5] 0 0
Change in ventilation from lung radiation therapy.
Timepoint [5] 0 0
8 weeks
Secondary outcome [6] 0 0
Physiological accuracy of CT perfusion imaging
Timepoint [6] 0 0
1 week
Secondary outcome [7] 0 0
Improvement in 4D PET image reconstruction using 4D attenuation CT
Timepoint [7] 0 0
1 week

Eligibility
Key inclusion criteria
* Aged 18 years or older.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
* Histologically proven Stage II-IV non-small cell lung cancer as determined using the IASLC International Association for the Study of Lung Cancer (IASLC) 8th edition lung cancer staging guidelines.
* To be treated with curative intent (stage II-III) or palliative intent (stage IV) with non-SABR external beam radiotherapy (e.g. 60 Gy in 30 treatments for curative intent or 30 Gy in 5 treatments for palliative intent).
* Pulmonary function tests within 8 weeks of registration.
* 4DCT simulation for radiation therapy.
* Willingness to give written informed consent.
* Willingness and ability to comply with the study procedures and visit requirements.
* Available for follow up for 1 year or until death, whichever occurs first.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior radiation therapy to the thorax.
* Prior surgery for this cancer.
* Prior chemotherapy for this cancer.
* Interstitial lung disease.
* Pregnant women.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/07/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2026
Actual
Sample size
Target
15
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 0 0
2065 - St Leonards

Funding & Sponsors
Primary sponsor type
Other
Name
University of Sydney
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
National Health and Medical Research Council, Australia
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Northern Sydney and Central Coast Area Health Service
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ricky O'Brien
Address 0 0
University of Sydney
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Trial Coordinator
Address 0 0
Country 0 0
Phone 0 0
+61 2 8627 1185
Fax 0 0
Email 0 0
Shona.Silvester@sydney.edu.au
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
After study completion, to maximise the scientific and clinical use of individual participant data (IPD) they will be made available to researchers for further scientific research. It will be stored at the University of Sydney and is likely to also be stored at an external research data repository archive or register, e.g. The Cancer Imaging Archive, and made publicly available. They may also be used in imaging scientific challenges, similar to previously scientific grand challenges we have led such as the SPARE and MATCH challenges.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR), Analytic code
When will data be available (start and end dates)?
After study completion and results published, IPD will be available indefinitely.
Available to whom?
IPD stored at the university: To download / decompress IPD, participating researchers will agree to the terms of use for the data, including that the data are not to be published or otherwise redistributed without the express consent of the original investigator(s).

IPD stored at an external repository: IPD will be stored at and managed by the external repository. IPD will only be shared with repositories whose function has been reviewed and approved by an accredited Research Integrity/Ethics Committee/Board.
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06159660